PL3302551T3 - Sposoby leczenia HER2-dodatniego, wcześniej nieleczonego przerzutowego raka sutka - Google Patents
Sposoby leczenia HER2-dodatniego, wcześniej nieleczonego przerzutowego raka sutkaInfo
- Publication number
- PL3302551T3 PL3302551T3 PL16730123.3T PL16730123T PL3302551T3 PL 3302551 T3 PL3302551 T3 PL 3302551T3 PL 16730123 T PL16730123 T PL 16730123T PL 3302551 T3 PL3302551 T3 PL 3302551T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- breast cancer
- metastatic breast
- previously untreated
- treating her2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168809P | 2015-05-30 | 2015-05-30 | |
| PCT/US2016/034835 WO2016196373A2 (en) | 2015-05-30 | 2016-05-27 | Methods of treating her2-positive metastatic breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3302551T3 true PL3302551T3 (pl) | 2024-09-30 |
Family
ID=56134616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16730123.3T PL3302551T3 (pl) | 2015-05-30 | 2016-05-27 | Sposoby leczenia HER2-dodatniego, wcześniej nieleczonego przerzutowego raka sutka |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11406715B2 (enExample) |
| EP (1) | EP3302551B1 (enExample) |
| JP (4) | JP6822980B2 (enExample) |
| CN (2) | CN121971642A (enExample) |
| DK (1) | DK3302551T3 (enExample) |
| ES (1) | ES2984592T3 (enExample) |
| FI (1) | FI3302551T3 (enExample) |
| HR (1) | HRP20241134T1 (enExample) |
| HU (1) | HUE068105T2 (enExample) |
| LT (1) | LT3302551T (enExample) |
| PL (1) | PL3302551T3 (enExample) |
| PT (1) | PT3302551T (enExample) |
| RS (1) | RS65871B1 (enExample) |
| SI (1) | SI3302551T1 (enExample) |
| WO (1) | WO2016196373A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210330801A1 (en) * | 2017-03-02 | 2021-10-28 | Cadila Healthcare Limited | Novel protein drug conjugate formulation |
| US20200114018A1 (en) * | 2018-10-15 | 2020-04-16 | Genentech, Inc. | Methods of treating residual breast cancer with trastuzumab emtansine |
| MA53933A (fr) | 2018-10-21 | 2021-08-25 | Slsg Ltd Llc | Poly-immunothérapie pour le traitement du cancer du sein triple-négatif |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| EP0474727B1 (en) | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| ES2293661T3 (es) | 1996-11-27 | 2008-03-16 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteinas a. |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| PT1064027E (pt) | 1998-03-27 | 2008-09-29 | Genentech Inc | Sinergismo de ligando de apo-2 e anticorpo anti-her-2 |
| ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| SI1187632T1 (sl) | 1999-05-14 | 2009-04-30 | Genentech Inc | Zdravljenje z anti-ErbB2 protitelesi |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| DE60033658T2 (de) | 1999-06-25 | 2007-11-22 | Genentech, Inc., South San Francisco | Behandlung von prostata-krebs mit anti-erbb2 antikörpern |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| EP2110138A1 (en) | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| WO2001089566A1 (en) | 2000-05-19 | 2001-11-29 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗ｈｅｒ２抗体改変体 |
| HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| PT1543038T (pt) | 2002-09-11 | 2017-07-07 | Genentech Inc | Purificação de proteína |
| EP1572972A4 (en) | 2002-11-21 | 2007-11-21 | Genentech Inc | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES |
| JP4599355B2 (ja) | 2003-07-28 | 2010-12-15 | ジェネンテック， インコーポレイテッド | プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減 |
| US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
| AU2005232657B2 (en) | 2004-04-08 | 2010-12-16 | David B. Agus | ErbB antagonists for pain therapy |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| UA90480C2 (uk) | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
| CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2587519A1 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
| RS53128B (sr) | 2005-02-23 | 2014-06-30 | Genentech Inc. | Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba |
| US20060204505A1 (en) | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| AU2007259171A1 (en) | 2006-06-05 | 2007-12-21 | F. Hoffmann-La Roche, Ag | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
| AU2007287794B2 (en) | 2006-08-21 | 2013-03-28 | F. Hoffmann-La Roche Ag | Tumor therapy with an anti-VEGF antibody |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| AU2008258859A1 (en) | 2007-06-06 | 2008-12-11 | F.Hoffmann-La Roche Ag | Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| HUE024877T2 (en) | 2007-10-30 | 2016-02-29 | Genentech Inc | Antibody purification by cation exchange chromatography |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| CL2009000545A1 (es) | 2008-03-06 | 2010-10-15 | Genentech Inc | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2011069074A2 (en) * | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| WO2012078771A1 (en) | 2010-12-09 | 2012-06-14 | Genentech, Inc. | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
-
2016
- 2016-05-27 JP JP2017561971A patent/JP6822980B2/ja active Active
- 2016-05-27 LT LTEPPCT/US2016/034835T patent/LT3302551T/lt unknown
- 2016-05-27 CN CN202511623386.6A patent/CN121971642A/zh active Pending
- 2016-05-27 FI FIEP16730123.3T patent/FI3302551T3/fi active
- 2016-05-27 RS RS20240909A patent/RS65871B1/sr unknown
- 2016-05-27 US US15/576,593 patent/US11406715B2/en active Active
- 2016-05-27 SI SI201631844T patent/SI3302551T1/sl unknown
- 2016-05-27 WO PCT/US2016/034835 patent/WO2016196373A2/en not_active Ceased
- 2016-05-27 HR HRP20241134TT patent/HRP20241134T1/hr unknown
- 2016-05-27 PT PT167301233T patent/PT3302551T/pt unknown
- 2016-05-27 ES ES16730123T patent/ES2984592T3/es active Active
- 2016-05-27 EP EP16730123.3A patent/EP3302551B1/en active Active
- 2016-05-27 PL PL16730123.3T patent/PL3302551T3/pl unknown
- 2016-05-27 DK DK16730123.3T patent/DK3302551T3/da active
- 2016-05-27 HU HUE16730123A patent/HUE068105T2/hu unknown
- 2016-05-27 CN CN201680031816.8A patent/CN107614015A/zh active Pending
-
2021
- 2021-01-07 JP JP2021001246A patent/JP7330217B2/ja active Active
-
2022
- 2022-07-19 US US17/813,466 patent/US20220354961A1/en not_active Abandoned
-
2023
- 2023-04-11 JP JP2023064033A patent/JP2023100635A/ja not_active Withdrawn
-
2025
- 2025-06-23 JP JP2025105921A patent/JP2025157247A/ja active Pending
- 2025-08-01 US US19/288,035 patent/US20260199508A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3302551B1 (en) | 2024-06-26 |
| LT3302551T (lt) | 2024-09-10 |
| HUE068105T2 (hu) | 2024-12-28 |
| WO2016196373A2 (en) | 2016-12-08 |
| JP2025157247A (ja) | 2025-10-15 |
| DK3302551T3 (da) | 2024-08-26 |
| JP2023100635A (ja) | 2023-07-19 |
| PT3302551T (pt) | 2024-08-21 |
| US20220354961A1 (en) | 2022-11-10 |
| HRP20241134T1 (hr) | 2024-11-22 |
| RS65871B1 (sr) | 2024-09-30 |
| JP6822980B2 (ja) | 2021-01-27 |
| FI3302551T3 (fi) | 2024-08-27 |
| JP7330217B2 (ja) | 2023-08-21 |
| ES2984592T3 (es) | 2024-10-30 |
| SI3302551T1 (sl) | 2024-10-30 |
| JP2021073203A (ja) | 2021-05-13 |
| US20190030181A1 (en) | 2019-01-31 |
| CN121971642A (zh) | 2026-05-05 |
| CN107614015A (zh) | 2018-01-19 |
| JP2018516920A (ja) | 2018-06-28 |
| US20260199508A1 (en) | 2026-07-16 |
| WO2016196373A3 (en) | 2017-02-02 |
| WO2016196373A8 (en) | 2017-11-30 |
| US11406715B2 (en) | 2022-08-09 |
| EP3302551A2 (en) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275663A (en) | Cancer treatment methods | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| IL255189A0 (en) | Cancer treatment methods | |
| IL255569A (en) | Methods of treating cancer using anti-ox40 antibodies | |
| SG10201913075RA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| IL266324A (en) | Treatment of her2-positive breast cancer | |
| IL262342A (en) | Cancer treatment methods | |
| PT3490560T (pt) | Niraparib para utilização num método de tratamento de cancro da próstata | |
| IL277981A (en) | Cancer treatment methods | |
| IL266917A (en) | Methods for treating prolactin receptor-positive breast cancer | |
| IL265697A (en) | Prostate cancer treatment | |
| ZA201802481B (en) | Novel biomarkers and methods of treating cancer | |
| IL271934A (en) | Methods for treating tumor metastases | |
| ZA201908539B (en) | Method of treatment of cancer | |
| IL281600B2 (en) | Cancer treatment methods | |
| SG11202010793UA (en) | Methods of treating cancer | |
| SG11202000839TA (en) | Methods of treating cancer by inhibiting setd2 | |
| GB201717945D0 (en) | Method for treatment of cancer | |
| SG11202005163PA (en) | Methods of treating cancer | |
| HUE068105T2 (hu) | Eljárások korábban kezeletlen her2-pozitív metasztatikus emlõrák kezelésére | |
| EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
| IL269123A (en) | Methods of treating cancer | |
| GB201510197D0 (en) | Method of treating ovarian cancer |